Update 3/19/14 Trading is mixed near flat line.
Cramer to pump Seattle Genetics (SGEN ($53.51 flat) today; on our focus list since’09 at $9.50.
Exact Sciences (EXAS) up ~3% on data release for Cologuard compared to FIT. Sensitivity of 92% with colorectal cancer and 42% with pre-cancerous lesions. (See detailed data). 2015 revenue forecasts from Yahoo are in range of $60M to $238M but will be updated no doubt.Volume of 5M shares and chart looks like profit taking.
Albany Molecular (AMRI $20.32) up 3.94% another new high.
————-
Rayno Biopharmaceutical and Diagnostic Stocks In BIG Rally
Biggest movers in Biopharma-Large Caps Still Rule Near All Time Highs
ALXN, AMGN, BIIB, GILD, REGN
Mid and Small Cap movers: AMRI, CBST, IMGN, SGEN
Achillion Pharmaceuticals (ACHN $3.54) our only loser is looking better. We added more at $3.40.
Diagnostic Stocks Pick Up Steam Up Over 2%: See EXAS
EXAS up 8% anticipating colorectal screening test approval. Data now in NEJM. Better than FIT. The stock was added to the Rayno portfolio on 12/10/10 at $5.60.
CPHD, GHDX, NSPH, QDEL, QGEN
Investment posture: maintain 15% cash, stay with Rayno Portfolio stocks, avoid high fliers and small cap speculative stocks. Using ETFs as a marker the sector is at the low end of a rising channel up 17% YTD.